North America Liquid Biopsy Market - 2023-2031
The North America Liquid Biopsy Market was valued at US$ 1464.00 million in 2023 and is anticipated to reach US$ 5110.34 million by 2031, at a CAGR of 0.171 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the North America Liquid Biopsy Market.
This report delivers a comprehensive overview of the North America Liquid Biopsy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding North America Liquid Biopsy Market. The North America Liquid Biopsy Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
North America Liquid Biopsy Market Scope:
By Circulating Biomarker
This report delivers a comprehensive overview of the North America Liquid Biopsy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding North America Liquid Biopsy Market. The North America Liquid Biopsy Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the North America Liquid Biopsy Market.
This report delivers a comprehensive overview of the North America Liquid Biopsy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding North America Liquid Biopsy Market. The North America Liquid Biopsy Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
North America Liquid Biopsy Market Scope:
By Circulating Biomarker
- Circulating Tumor Cells
- Circulating Tumor DNA (ctDNA)
- Cell-free DNA (cfDNA)
- Extracellular Vesicles
- Kits & Reagents
- Instruments
- Services
- Cancer Applications
- Non-Cancer Applications
- Multi-gene-parallel Analysis (NGS)
- Single Gene Analysis (PCR Microarrays)
- Hospitals and Physician Laboratories
- Research Centers
- Others
- Bio-Rad Laboratories
- F. Hoffmann-La Roche AG
- Exosome Sciences Inc.
- Grail Inc
- Guardant Health
- Thermo Fisher Scientific Inc.
- Inivata Ltd
- Illumina Inc
- LungLife AI Inc
- Qiagen NV
This report delivers a comprehensive overview of the North America Liquid Biopsy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding North America Liquid Biopsy Market. The North America Liquid Biopsy Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Circulating Biomarker
3.2. Snippet by Product & Services
3.3. Snippet by Application
3.4. Snippet by Technology
3.5. Snippet by End User
3.6. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Recent Advances in Liquid Biopsy Technologies for Cancer Biomarker Detection
4.1.1.2. Emerging Liquid Biopsy Techniques for Blood-based Detection of Tumor DNA
4.1.2. Restraints
4.1.2.1. Challenges in the Development of Liquid Biopsy Kits
4.1.3. Opportunity
4.1.3.1. Increasing Research Collaborations
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. RUSSIA-UKRAINE WAR ANALYSIS
8. BY CIRCULATING BIOMARKER
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
8.1.2. Market Attractiveness Index, By Circulating Biomarker
8.2. Circulating Tumor Cells*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Circulating Tumor DNA (ctDNA)
8.4. Cell-free DNA (cfDNA)
8.5. Extracellular Vesicles
9. BY PRODUCT & SERVICES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Services
9.1.2. Market Attractiveness Index, By Product & Services
9.2. Kits & Reagents*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Instruments
9.4. Services
10. BY APPLICATION
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.1.2. Market Attractiveness Index, By Application
10.2. Cancer Applications*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.2.3. Breast Cancer
10.2.4. Colorectal Cancer
10.2.5. Lung Cancer
10.2.6. Prostate Cancer
10.2.7. Liver Cancer
10.2.8. Other
10.3. Non-Cancer Applications
10.3.1. Non-Invasive Prenatal Testing (NIPT)
10.3.2. Organ Transplantations
10.3.3. Infectious Disease Testing
11. BY TECHNOLOGY
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.1.2. Market Attractiveness Index, By Technology
11.2. Multi-gene-parallel Analysis (NGS)*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Single Gene Analysis (PCR Microarrays)
12. BY END USER
12.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.2. Market Attractiveness Index, By End User
12.3. Hospitals and Physician Laboratories*
12.3.1. Introduction
12.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.4. Research Centers
12.5. Others
13. BY COUNTRY
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
13.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
13.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
13.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
13.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
13.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
13.2.8.1. The U.S.
13.2.8.2. Canada
13.2.8.3. Mexico
14. COMPETITIVE LANDSCAPE
14.1. Competitive Scenario
14.2. Product Benchmarking
14.3. Company Share Analysis
14.4. Key Developments and Strategies
15. COMPANY PROFILES
15.1. Bio-Rad Laboratories*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. F. Hoffmann-La Roche AG
15.3. Exosome Sciences Inc.
15.4. Grail Inc
15.5. Guardant Health
15.6. Thermo Fisher Scientific Inc.
15.7. Inivata Ltd
15.8. Illumina Inc
15.9. LungLife AI Inc
15.10. Qiagen NV (*LIST NOT EXHAUSTIVE)
16. APPENDIX
16.1. About Us and Services
16.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Circulating Biomarker
3.2. Snippet by Product & Services
3.3. Snippet by Application
3.4. Snippet by Technology
3.5. Snippet by End User
3.6. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Recent Advances in Liquid Biopsy Technologies for Cancer Biomarker Detection
4.1.1.2. Emerging Liquid Biopsy Techniques for Blood-based Detection of Tumor DNA
4.1.2. Restraints
4.1.2.1. Challenges in the Development of Liquid Biopsy Kits
4.1.3. Opportunity
4.1.3.1. Increasing Research Collaborations
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. RUSSIA-UKRAINE WAR ANALYSIS
8. BY CIRCULATING BIOMARKER
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
8.1.2. Market Attractiveness Index, By Circulating Biomarker
8.2. Circulating Tumor Cells*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Circulating Tumor DNA (ctDNA)
8.4. Cell-free DNA (cfDNA)
8.5. Extracellular Vesicles
9. BY PRODUCT & SERVICES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Services
9.1.2. Market Attractiveness Index, By Product & Services
9.2. Kits & Reagents*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Instruments
9.4. Services
10. BY APPLICATION
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.1.2. Market Attractiveness Index, By Application
10.2. Cancer Applications*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.2.3. Breast Cancer
10.2.4. Colorectal Cancer
10.2.5. Lung Cancer
10.2.6. Prostate Cancer
10.2.7. Liver Cancer
10.2.8. Other
10.3. Non-Cancer Applications
10.3.1. Non-Invasive Prenatal Testing (NIPT)
10.3.2. Organ Transplantations
10.3.3. Infectious Disease Testing
11. BY TECHNOLOGY
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.1.2. Market Attractiveness Index, By Technology
11.2. Multi-gene-parallel Analysis (NGS)*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Single Gene Analysis (PCR Microarrays)
12. BY END USER
12.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.2. Market Attractiveness Index, By End User
12.3. Hospitals and Physician Laboratories*
12.3.1. Introduction
12.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.4. Research Centers
12.5. Others
13. BY COUNTRY
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
13.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
13.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
13.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
13.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
13.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
13.2.8.1. The U.S.
13.2.8.2. Canada
13.2.8.3. Mexico
14. COMPETITIVE LANDSCAPE
14.1. Competitive Scenario
14.2. Product Benchmarking
14.3. Company Share Analysis
14.4. Key Developments and Strategies
15. COMPANY PROFILES
15.1. Bio-Rad Laboratories*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. F. Hoffmann-La Roche AG
15.3. Exosome Sciences Inc.
15.4. Grail Inc
15.5. Guardant Health
15.6. Thermo Fisher Scientific Inc.
15.7. Inivata Ltd
15.8. Illumina Inc
15.9. LungLife AI Inc
15.10. Qiagen NV (*LIST NOT EXHAUSTIVE)
16. APPENDIX
16.1. About Us and Services
16.2. Contact Us
